GSTP1 rs1695 is associated with both hematological toxicity and prognosis of ovarian cancer treated with paclitaxel plus carboplatin combination chemotherapy: a comprehensive analysis using targeted resequencing of 100 pharmacogenes

PURPOSE: To find genetic variants that predicted toxicity and/or efficacy of paclitaxel plus carboplatin combination therapy (TC therapy). PATIENTS AND METHODS: In a retrospective case-control study, we analyzed 320 patients who had received TC therapy for gynecological cancers (ovarian, fallopian t...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoshihama, Tomoko, Fukunaga, Koya, Hirasawa, Akira, Nomura, Hiroyuki, Akahane, Tomoko, Kataoka, Fumio, Yamagami, Wataru, Aoki, Daisuke, Mushiroda, Taisei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6049855/
https://www.ncbi.nlm.nih.gov/pubmed/30038720
http://dx.doi.org/10.18632/oncotarget.25712

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6049855/
https://www.ncbi.nlm.nih.gov/pubmed/30038720
http://dx.doi.org/10.18632/oncotarget.25712

Ejemplares similares